• Home
  • Search Results

Search Results

Cancer
Cancer - Lymphoma
Cancer - Multiple Myeloma
Young Adult (18-34)
Adult (35-64)
Older Adult (65+)
Open
31 studies match your search
Open

Cancer Research Study for Bertie, Hertford, Robeson & Scotland Co, NC and neighboring counties

We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
Visit Location
100% Remote (online, phone, text)
Open

Young Adult Cancer Survivors Healthy Eating and Active Lifestyle Study

Are you a young adult cancer survivor who would like to improve your health? Interested in using technology to support a healthy diet, get more physically active, and make healthy lifestyle changes? Researchers at the University of North Carolina at Chapel Hill are looking for volunteers to sign up for a 3-month research program using a Fitbit activity tracker and mobile app to improve your physical activity and dietary habits.

Age & Gender
  • 18 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Eating, Nutrition, and Metabolism
  • Wellness and Lifestyle
  • and 3 more
Visit Location
100% Remote (online, phone, text)
Open

Selinexor, Dara, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or RMM

Have you been diagnosed with high-risk, relapsed or relapsed/refractory Multiple Myeloma and have already received 1-3 different types of therapy? If so, you may be eligible for our phase 2 study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Multiple Myeloma)
Open

Multi-cancer Early Detection Blood Tests

Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.

Age & Gender
  • 40 years ~ 75 years
  • Male, Female
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 13 more)
  • Healthy Volunteer or General Population
Open

ETERNITY: Biorepository to accelerate advances in Radiation Therapy

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

Age & Gender
  • 0 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
  • Child and Teen Health
Open

Phase 2 Study of Istatuximab Plus Pomalidomide and Dexamethasone for Elderly and Frail Patients with Relapsed or Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and effectiveness of giving a combination of treatments to patients with relapsed or refractory multiple myeloma who are toxicity-vulnerable.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Phase 2 study of isatuximab plus lenalidomide and dexamethasone in highly toxicity-vulnerable subjects with newly diagnosed multiple myeloma

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Relapsed or Refractory Multiple Myeloma: Safety and Dose Optimization of ABBV-383

Have you been diagnosed with multiple myeloma that has not responded to treatment or has come back after treatment? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called ABBV-383 to patients with relapsed/refractory multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Phase 1 Trials (all cancers), Multiple Myeloma)
Open

Smoldering Multiple Myeloma Study

Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research